Business Context and Reporting Period
This Form 6-K filing by Psyence Biomedical Ltd. covers the month of July 2024. The report details the entry into a material agreement on July 25, 2024, with WhiteLion Capital, LLC ("White Lion"), consisting of a Common Stock Purchase Agreement and a Registration Rights Agreement.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, or margin data for the reporting period. The primary financial metric disclosed is the potential capital raise:
- Aggregate Commitment: Up to $25,000,000 in gross purchase price for newly issued common shares.
- Commitment Shares: The Company agreed to issue shares valued at $187,500 to White Lion as consideration for the commitment, payable in two tranches based on closing prices.
Material Changes
The material change reported is the execution of the Common Stock Purchase Agreement, which grants the Company the right, but not the obligation, to sell shares to White Lion over a two-year period or until the $25,000,000 cap is reached. Key terms include:
- Fixed Purchase Notice: Allows the Company to require purchases up to the lesser of $250,000 or 50% of the Average Daily Trading Volume (ADTV). The price is set at 90% of the lowest VWAP over the five business days prior to the notice.
- Rapid Purchase Notice: Allows the Company to require purchases up to the lesser of 30% of ADTV or $4,000,000 divided by the highest closing price over the prior five business days. The price is the lowest traded price on the notice date.
- Ownership Cap: White Lion cannot beneficially own more than 4.99% of outstanding shares (waivable to 9.99%) immediately prior to issuance.
Guidance, Outlook, and Risks
Outlook: The agreement provides a potential source of liquidity for the Company over the next two years, subject to market conditions and trading volume limits.
Risks and Contingencies:
- Dilution: Issuance of shares will dilute existing shareholders.
- Termination: The agreement terminates automatically if the Company commences voluntary bankruptcy, a custodian is appointed, or a general assignment for the benefit of creditors is made.
- Registration: The Company must file a resale registration statement within 30 days of execution; failure to do so may trigger damages provisions.
- Commitment Shares: The $187,500 worth of Commitment Shares are fully earned by White Lion regardless of whether the Purchase Agreement is terminated.
Investor Verification Checklist
- Verify the current trading volume and price of Psyence Biomedical Ltd. common stock to assess the practical limits of the Fixed and Rapid Purchase Notices.
- Review the full text of the Common Stock Purchase Agreement (Exhibit 99.1) for specific conditions precedent and limitations not detailed in the summary.
- Confirm the status of the resale registration statement filing required within 30 days of July 25, 2024.
- Monitor the issuance of the $187,500 Commitment Shares and their impact on the share count.